Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca and its subsidiary MedImmune have reported that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.
Navamedic, a Norwegian medtech and pharmaceutical products company, has reported loss before tax of €0.3 million for the first quarter of 2017, which is increase compared to €0.7 million for the same period last year.
Biocartis Group has appointed Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017.
NIH-funded clinical trial shows use of either drug improved vision and had few side effects.
Healthcare conglomerate Johnson & Johnson <JNJ.N> said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.
Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
Faron Pharmaceuticals has received the Independent Data Monitoring Committee’s (IDMC) recommendation to continue the INTEREST Phase III study for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) with its lead product Traumakine.
Its have been three years since Ice bucket challenge went viral promoting awareness of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease and encourage donations to research.